LFSC.US F/m Emerald Life Sciences Innovation ETF
- Total assets
- 130M
- Expense ratio
- -
- Dividend yield
- -
- 1-year return
- +32.27%
- Holdings
- 38
- Since
- 2024
Fund data as reported by the issuer, updated Nov 15, 2026. Total assets are in the fund's base currency.
What does LFSC.US invest in?
- Mostly US stocks (97.4%)
- Largest sector: Healthcare (100.0%)
- Largest region: North America (100.0%)
- Top 3 holdings: 24.0% of the fund
Asset allocation
- US stocks 97.4%
- Bonds 0.4%
- Cash 0.1%
- Other 0.0%
Top holdings
- Replimune Group Inc 10.98%
- LivaNova PLC 7.35%
- Travere Therapeutics Inc 5.67%
- Cogent Biosciences Inc 5.31%
- BillionToOne, Inc. Class A Common Stock 4.79%
F/m Emerald Life Sciences Innovation ETF performance
Sharpe ratio 0.00- This year
- +26.93%
- 1 year
- +32.27%
- 3 years
- -
- 5 years
- -
Volatility 24.7% over 1 year. High: expect large swings.
Total returns in the fund's currency as reported by the issuer; past returns do not predict future returns. Volatility is the yearly standard deviation of returns. Ask AI to explain these numbers
LFSC.US price
Prices on the chart can differ slightly from the closing prices StockSummer shows.
About F/m Emerald Life Sciences Innovation ETF
The fund is an actively managed exchange-traded fund ("ETF") and invests primarily in equity securities of life science companies selected by Emerald Mutual Fund Advisers Trust, the fund"s investment sub-adviser, under the supervision of the adviser. Under normal market conditions, the fund invests at least 80% of its net assets in equity securities issued by life science companies demonstrating innovation.
Full fund profileF/m Emerald Life Sciences Innovation ETF top holdings
54.7% of the fund| Holding | Sector | Country | Weight |
|---|---|---|---|
| Replimune Group Inc REPL.US | Healthcare | United States | 10.98% |
| LivaNova PLC LIVN.US | Healthcare | United States | 7.35% |
| Travere Therapeutics Inc TVTX.US | Healthcare | United States | 5.67% |
| Cogent Biosciences Inc UMRX.US | Healthcare | United States | 5.31% |
| BillionToOne, Inc. Class A Common Stock BLLN.US | Healthcare | United States | 4.79% |
| Guardant Health Inc GH.US | Healthcare | United States | 4.73% |
| Corcept Therapeutics Incorporated CORT.US | Healthcare | United States | 4.20% |
| Spyre Therapeutics Inc. SYRE.US | Healthcare | United States | 4.09% |
| United Therapeutics Corporation UTHR.US | Healthcare | United States | 3.81% |
| Veradermics, Incorporated MANE.US | Healthcare | United States | 3.80% |
The 10 largest of 38 holdings.
LFSC.US sector exposure
- Healthcare100.0%
Share of the stocks in the fund.
LFSC.US regional exposure
- North America100.0%
Share of the stocks in the fund.
Company size
Average market cap 4.36B- Medium cap8.4%
- Small cap52.5%
- Micro cap33.2%
F/m Emerald Life Sciences Innovation ETF fund profile
- Fund name
- F/m Emerald Life Sciences Innovation ETF
- Ticker
- LFSC.US
- Exchange
- USA Stocks
- Issuer
- Emerald Mutual Fund Advisers Trust
- Index tracked
- -
- Category
- Healthcare Equity
- Inception date
- Oct 30, 2024
- Trading currency
- USD
- Expense ratio
- -
About F/m Emerald Life Sciences Innovation ETF
The fund is an actively managed exchange-traded fund ("ETF") and invests primarily in equity securities of life science companies selected by Emerald Mutual Fund Advisers Trust, the fund"s investment sub-adviser, under the supervision of the adviser. Under normal market conditions, the fund invests at least 80% of its net assets in equity securities issued by life science companies demonstrating innovation.